

## IDSC Publications

---

1. Adjei AA, Christian M, Ivy P. *Novel designs and end points for phase II clinical trials*. Clin Cancer Res 2009;**15**(6):1866-72.
2. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, et al. *Principles and Current Strategies for Targeting Autophagy for Cancer Treatment*. Clin Cancer Res 2011;**17**(4):654-666.
3. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, et al. *Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway*. J Clin Oncol 2012;**30**(23):2919-28.
4. Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, et al. *Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents*. Clin Cancer Res 2010;**16**(6):1745-55.
5. Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ. *Alternate endpoints for screening phase II studies*. Clin Cancer Res 2009;**15**(6):1873-82.
6. Forster MD, Saijo N, Seymour L, Calvert H. *Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan*. Clin Cancer Res 2010;**16**(6):1737-44.
7. Hewitt SM, Badve SS, True LD. *Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy*. Clin Cancer Res 2012;**18**(6):1524-30.
8. Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. *Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee*. Clin Cancer Res 2010;**16**(6):1726-36.
9. LaBarge MA. *The difficulty of targeting cancer stem cell niches*. Clin Cancer Res 2010;**16**(12):3121-9.
10. LoRusso PM, Boerner SA, Seymour L. *An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics*. Clin Cancer Res 2010;**16**(6):1710-8.
11. Maitland ML. *Cardiovascular toxicity of new agents*. Clin Adv Hematol Oncol 2008;**6**(9):657-9.

## IDSC Publications

---

12. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. *Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors*. J Natl Cancer Inst 2010;**102**(9):596-604.
13. McShane LM, Hunsberger S, Adjei AA. *Effective incorporation of biomarkers into phase II trials*. Clin Cancer Res 2009;**15**(6):1898-905.
14. Merchant AA, Matsui W. *Targeting Hedgehog--a cancer stem cell pathway*. Clin Cancer Res 2010;**16**(12):3130-40.
15. Meshinchi S, Hunger SP, Aplenc R, Adamson PC, Jessup JM. *Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031*. Clin Cancer Res 2012;**18**(6):1547-54.
16. O'Brien CA, Kreso A, Jamieson CH. *Cancer stem cells and self-renewal*. Clin Cancer Res 2010;**16**(12):3113-20.
17. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, et al. *Targeting Notch to target cancer stem cells*. Clin Cancer Res 2010;**16**(12):3141-52.
18. Philip PA, Chansky K, Rubinstein L, LeBlanc M, Seymour L, Ivy SO, et al. *Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single Arm Phase II Trials*. Clin Cancer Res 2014.
19. Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt SM, Jessup JM. *Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development*. Clin Cancer Res 2012;**18**(6):1515-23.
20. Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D. *Randomized phase II designs*. Clin Cancer Res 2009;**15**(6):1883-90.
21. Sargent DJ, Taylor JM. *Current issues in oncology drug development, with a focus on Phase II trials*. J Biopharm Stat 2009;**19**(3):556-62.
22. Schilsky RL, Doroshow JH, Leblanc M, Conley BA. *Development and use of integral assays in clinical trials*. Clin Cancer Res 2012;**18**(6):1540-6.
23. Seymour L. *Controversies in the Design of Phase II Clinical Trials*. Clinical Advances in Hematology & Oncology 2010;**8**(2):95-97.
24. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, et al. *The design of phase II clinical trials testing cancer therapeutics: consensus*

## IDSC Publications

---

*recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res*

2010;**16**(6):1764-9.

25. Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ.

*Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res* 2009;**15**(6):1891-7.

26. Takebe N, Ivy SP. *Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin Cancer Res* 2010;**16**(12):3106-12.

27. Weber JS, Atkins MB, Hwu P, Radvanyi L, Sznol M, Yee C. *White Paper on Adoptive Cell Therapy for Cancer with Tumor Infiltrating Lymphocytes: a report of the CTEP Subcommittee on Adoptive Cell Therapy. Clin Cancer Res* 2011.

28. Williams PM, Lively TG, Jessup JM, Conley BA. *Bridging the gap: moving predictive and prognostic assays from research to clinical use. Clin Cancer Res* 2012;**18**(6):1531-9.